SCHEMBL21959072

SCHEMBL21959072

Cc1cc(=O)c2cccc(Cl)c2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 3/20 0.46
▸ TTR P02766 3/20 0.44
▸ CYP1A1 P04798 5/20 0.43
▸ CYP1A2 P05177 5/20 0.43
▸ CYP1B1 Q16678 5/20 0.43
▸ MAPT P10636 3/20 0.40
▸ HTT P42858 1/20 0.40
▸ PAX8 Q06710 1/20 0.40
▸ NR3C2 P08235 2/20 0.39
▸ PRKDC P78527 1/20 0.39
▸ GPR35 Q9HC97 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ CYP3A4 P08684 2/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ PTGS2 P35354 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1319784 0.81 PRKDC (0.55) CYP1A1CYP1A2CYP1B1MAPTNR3C2
SCHEMBL29677981 0.81 PRKDC (0.55) CYP1A1CYP1A2CYP1B1MAPTNR3C2
SCHEMBL27861122 0.79 LOXL2 (0.58) CYP1A2MAPTNR3C2GPR35ACHE
SCHEMBL21959063 0.76 CSNK2A2 (0.48) AHRCYP1A1CYP1A2CYP1B1MAPT
SCHEMBL1320093 0.76 ALDH1A1 (0.39) CYP1A1CYP1A2CYP1B1MAPTNR3C2
SCHEMBL28592427 0.76 ALDH1A1 (0.64) CYP1A1CYP1A2CYP1B1MAPTPRKDC
SCHEMBL12325495 0.75 LOXL2 (0.47) AHRTTRCYP1A1CYP1A2CYP1B1
SCHEMBL5564222 0.75 GPR35 (0.61) TTRGPR35PTGS1KDM4EALDH1A1
SCHEMBL9160788 0.75 CYP1A2 (0.40) CYP1A1CYP1A2CYP1B1MAPTNR3C2
SCHEMBL31217606 0.75 PRKDC (0.57) CYP1A1CYP1A2CYP1B1MAPTPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020079106-A1 CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-04-23 — — WO disclosed
Send feedback